.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020

Experts in multiple sclerosis review top data presented at the 8th joint ACTRIMS-ECTRIMS meeting.

EP. 1: Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

November 24th 2020

EP. 2: OLKIOS: Looking at Ofatumumab’s Continued Efficacy

November 24th 2020

EP. 3: OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

November 24th 2020

EP. 4: Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

November 24th 2020

EP. 5: Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

November 24th 2020

EP. 6: Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

November 24th 2020

EP. 7: OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

November 24th 2020

EP. 8: OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

November 24th 2020

EP. 9: Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

November 24th 2020

EP. 10: Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

November 24th 2020